Fosun Internatio Stock Price, News & Analysis

Fosun International (OTC:FOSUY) has been recognized in Fortune China's 2025 "Most Admired Chinese Companies" Industry Star List, highlighting its excellence in ESG, employee responsibility, and stakeholder value creation.

The company achieved significant milestones in H1 2025, including the development of HLX43, the world's first PD-L1-targeting antibody-drug conjugate in Phase II trials, and the expansion of Yi Kai Da cancer therapy to over 200 treatment centers across 28 provinces. The company's artesunate injection has treated over 84 million malaria patients globally, while its Rural Doctors Program has supported 25,000 rural doctors, benefiting 16.34 million rural residents.

Fosun maintains strong ESG performance, ranking in the top 1% in S&P Global's Sustainability Yearbook 2025 (China Edition) and securing inclusion in the FTSE4Good Index Series for the fourth consecutive year.

Fosun International (OTC:FOSUY) presented its H1 2025 interim results, highlighting significant achievements in innovation and global expansion. The company reported total revenue of RMB87.28 billion, with overseas revenue accounting for 53% of total revenue. The Group's industrial operation profit reached RMB3.15 billion, while profit attributable to owners was RMB661.2 million.

The company's four core subsidiaries - Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group - contributed 73% of total revenue at RMB63.61 billion. Management emphasized its focus on innovation, particularly in biopharmaceuticals, and its commitment to debt reduction, targeting interest-bearing debt of RMB60 billion or less while maintaining a current healthy debt-to-capital ratio of 53%.

Fosun International (OTC:FOSUY) Chairman Guo Guangchang outlined the company's strategic vision during its 2025 interim results presentation, emphasizing continued investment in biopharmaceuticals and focus on established advantageous sectors. The company has made significant breakthroughs in its pharmaceutical segment, with a robust pipeline of innovative drugs including Henlius products and Fosun Kite's CAR-T therapy.

Highlighting Fosun's commitment to global expansion, Guangchang emphasized the company's dedication to building global R&D, clinical, and sales capabilities. The chairman noted that establishing competitive strength requires long-term investment, citing Henlius's RMB10 billion investment over 15 years and the recent profitability of its insurance ventures.

The company maintains its vision of helping people live healthily to age 121, with a particular focus on making cancer curable through comprehensive treatment approaches combining drugs, devices, and multi-molecule therapies.

Fosun International (OTC:FOSUY) released its 2025 interim results, reporting total revenue of RMB87.28 billion and profit attributable to owners of RMB661.2 million. The company's four core subsidiaries generated RMB63.61 billion in revenue, representing 73% of total revenue.

Key highlights include RMB3.6 billion investment in technology and innovation, with significant breakthroughs in innovative drugs, particularly HLX43's global Phase II clinical trials. Overseas revenue reached RMB46.67 billion, accounting for 53% of total revenue. The company maintained a healthy debt ratio of 53% and received a "Stable" outlook from S&P.

Notable achievements include Fosun Pharma's 38.96% profit growth, Fosun Insurance Portugal's 27.6% net profit increase, and FTG's record business volume of RMB9.53 billion with 42% adjusted net profit growth year-on-year.

Fidelidade (FOSUY), a core subsidiary of Fosun International, has received an 'A' rating with stable outlook from Standard & Poor's (S&P) for both its insurance and reinsurance operations. This follows Fitch's A+ rating upgrade in September 2024, marking Fidelidade as the highest-rated Portuguese company.

The company demonstrated strong performance in 2024 with 12.6% growth in insurance revenues and net income of EUR173.5 million. Fidelidade maintains a 30% market share in Portugal and has expanded internationally across Europe, Africa, Latin America, and Asia, with international operations now representing 30% of total premiums. The company's solid financial position is reflected in its Solvency II ratio of 194% at year-end 2024.

[ "Received 'A' rating from S&P and A+ rating from Fitch", "Strong 12.6% growth in insurance revenues for 2024", "Robust Solvency II ratio of 194%", "Significant international diversification with 30% of premiums from international operations", "Leading market position with 30% share in Portugal" ]

Fosun International (OTC:FOSUY) has achieved significant recognition in its ESG performance, with its FTSE Russell ESG rating upgraded to 3.9 in 2025, surpassing both the global industry average of 2.6 and the national average of 2.0.

The company secured perfect scores of 5.0 in Environmental Supply Chain, Anti-Corruption, and Risk Management. Fosun has maintained its position in the FTSE4Good Index Series for four consecutive years and holds notable ratings including an MSCI ESG rating of AA, HSI ESG rating of AA-, and ranks in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment.

Fosun International Limited (OTC:FOSUY) has completed the sale of its 99.743% stake in German private bank Hauck Aufhäuser Lampe Privatbank AG (HAL) for EUR670 million. The transaction, completed on June 30, 2025, delivered a double-digit internal rate of return (IRR) for Fosun.

While divesting HAL's banking business, Fosun retains full ownership of Hauck & Aufhäuser Fund Services S.A. (HAFS), its valuable asset servicing business that manages over EUR100 billion in assets across Luxembourg, Ireland, and German-speaking regions. HAFS will continue collaborating with HAL for fund administration services.

This strategic move aligns with Fosun's asset-light operating strategy and focus on core businesses. The company plans to increase investments in key sectors including biopharmaceuticals, cultural tourism, insurance, and healthcare, while pursuing its goal of achieving RMB10 billion in annual profits.

Fosun International (OTC:FOSUY) has received five prestigious awards from Corporate Governance Asia, including recognition for its Co-CEOs and corporate sustainability efforts. Executive Directors and Co-CEOs Chen Qiyu and Xu Xiaoliang were both honored with Asia's Best CEO awards, while the company secured the Sustainable Asia Award 2025, Best Environmental Responsibility Award, and Best Corporate Communications Award.

The company has demonstrated significant achievements in ESG initiatives, maintaining an MSCI ESG rating of AA and ranking in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment. Fosun has committed to reaching carbon neutrality by 2050 and achieving peak carbon emissions by 2028.

In healthcare innovation, the company reported that its drug HANSIZHUANG received European Union approval in early 2025 as the first PD-1 innovative drug for first-line treatment of extensive-stage small cell lung cancer. Additionally, Fosun's artesunate injection has treated over 80 million severe malaria patients globally, while its CAR-T cell therapy has benefited more than 800 lymphoma patients in mainland China.

Fosun International (FOSUY) has been awarded three prestigious honors by Global Banking and Finance Review: Best Sustainable Development Company Asia 2025, Best CSR Company Asia 2025, and Holding Group Brand of the Year Asia 2025. The company's ESG strategy "Create IMPACT" focuses on six key areas: Innovation-driven, Mindful Operation, People and Partner Oriented, Advanced Governance, Climate and Planet Positive, and Transparency. Fosun maintains an MSCI ESG rating of AA and ranks in the top 5% among global peers in S&P Global's CSA. Notable achievements include their Rural Doctors Program supporting 25,000 doctors and benefiting 3 million rural families, and Henlius' HANSIZHUANG becoming the first PD-1 drug approved for ES-SCLC treatment in the EU. Fosun Pharma's artesunate injection has saved over 80 million severe malaria patients globally. The company operates across 35+ countries and joined the UN Global Compact in 2014, demonstrating commitment to sustainable global development.